# Exercise and Olanzapine-samidorphan

> **NCT06740890** · PHASE4 · RECRUITING · sponsor: **New York State Psychiatric Institute** · enrollment: 30 (estimated)

## Conditions studied

- Schizophenia Disorder
- Schizoaffective Disorder
- Bipolar Disorder I or II
- Bipolar Disorder NOS

## Interventions

- **DRUG:** Olanzapine-samidorphan + exercise

## Key facts

- **NCT ID:** NCT06740890
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-26
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06740890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06740890, "Exercise and Olanzapine-samidorphan". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06740890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*